Peptide Monograph
MGF
Mechano Growth Factor (IGF-1Ec Splice Variant)
At a Glance
Mechanism of Action
MGF (Mechano Growth Factor) is a splice variant of the insulin-like growth factor 1 (IGF-1) gene that is expressed in muscle tissue in response to mechanical overload and damage. The discovery and characterization of MGF is primarily attributed to the work of Geoffrey Goldspink and colleagues at University College London, who identified that the IGF-1 gene undergoes alternative splicing in response to mechanical stimulation, producing distinct isoforms with different biological activities.[1]
In humans, the IGF-1 gene produces three primary splice variants: IGF-1Ea (the liver-derived systemic form), IGF-1Eb, and IGF-1Ec (the mechano-sensitive form, designated MGF). These variants share the same mature IGF-1 peptide (exons 3 and 4) but differ in their E-domain extensions (encoded by exons 5 and 6). The MGF isoform (IGF-1Ec) includes a unique 49-base insert from exon 5 that creates a reading frame shift, producing a distinctive 24-amino-acid C-terminal peptide that is not present in other IGF-1 isoforms.[1][2]
The key biological distinction between MGF and the mature IGF-1Ea isoform lies in their effects on muscle satellite cells (muscle stem cells). Goldspink and Yang demonstrated that the MGF E-domain peptide specifically promotes satellite cell proliferation without differentiation, effectively expanding the pool of muscle precursor cells. In contrast, the mature IGF-1Ea isoform primarily drives differentiation and fusion of existing satellite cells into mature muscle fibers. This temporal pattern suggests that MGF acts as an early response signal following muscle damage, initiating satellite cell activation and proliferation, while IGF-1Ea subsequently drives the differentiation phase of muscle repair.[2][3]
Hill and Goldspink demonstrated that MGF expression is rapidly upregulated in muscle following mechanical overload (exercise), with peak expression occurring within hours of the stimulus and declining rapidly thereafter. This transient expression pattern is consistent with MGF's proposed role as an early damage-response signal, in contrast to the sustained expression of systemic IGF-1Ea.[4]
The synthetic MGF peptide available as a research chemical consists of the 24-amino-acid C-terminal E-domain peptide that is unique to the MGF splice variant. This is distinct from the full-length MGF protein, which also contains the complete mature IGF-1 sequence. A critical unresolved question is whether this 24-amino-acid fragment recapitulates the full biological activity of the complete MGF protein.
Native MGF peptide has an extremely short half-life of approximately 5–7 minutes due to rapid enzymatic degradation. This has led to the development of PEGylated MGF (PEG-MGF), in which a polyethylene glycol chain is attached to the peptide to resist degradation and extend the half-life to several hours. However, PEGylation may alter the peptide's biological activity and tissue distribution. The practical utility of non-PEGylated MGF is questionable given its near-instantaneous degradation.
Evidence Summary
The evidence base for MGF consists primarily of in vitro cell culture studies and animal models, largely from a single research group (Goldspink et al., University College London). Published research overwhelmingly uses the full-length MGF protein or gene expression analysis, not the 24-amino-acid synthetic peptide fragment sold as a research chemical. No human clinical trials have been conducted with synthetic MGF peptide.
In Vitro and Gene Expression Studies
Yang and Goldspink demonstrated that the MGF E-domain peptide activates satellite cells in vitro, promoting proliferation without inducing differentiation. This was shown through increased expression of MyoD (a satellite cell activation marker) without upregulation of myogenin (a terminal differentiation marker), supporting the model that MGF specifically expands the satellite cell pool.[2]
Hill and Goldspink showed that MGF mRNA is rapidly upregulated in rabbit extensor digitorum longus muscle following electrical stimulation mimicking exercise, with peak expression at 24 hours and rapid decline thereafter. This study established the temporal pattern of MGF expression following mechanical stimulation.[4]
Animal Studies
Goldspink et al. demonstrated that intramuscular injection of an MGF-encoding plasmid (gene transfer, not synthetic peptide) into mouse muscle produced a 25% increase in muscle fiber cross-sectional area within two weeks. This gene transfer approach provides continuous local MGF expression, which is pharmacologically distinct from bolus injection of the synthetic 24-amino-acid peptide fragment.[1]
Human Expression Studies
Hameed et al. demonstrated that MGF mRNA expression is upregulated in human muscle following resistance exercise, and that this response is blunted in elderly individuals compared to young adults. This age-related decline in MGF expression has been proposed as a contributor to sarcopenia (age-related muscle loss), and has been cited as a rationale for exogenous MGF supplementation in older populations, though this hypothesis remains untested.[5]
Synthetic Peptide Evidence Gap
A critical limitation of the MGF evidence base is that published research primarily uses gene expression analysis, gene transfer (plasmid injection), or the full-length MGF protein. The extent to which the commercially available 24-amino-acid C-terminal synthetic peptide fragment reproduces the biological activity of the full MGF protein is unclear. The 24-AA fragment lacks the mature IGF-1 core sequence, so its mechanism of action would necessarily differ from the full-length protein.
Primary Uses (in Research)
Based on the available preclinical literature, MGF has been investigated for the following applications:
- Muscle satellite cell activation — The primary proposed application. MGF's unique ability to promote satellite cell proliferation without differentiation suggests a role in expanding the muscle precursor cell pool, which could enhance muscle repair capacity and potentially support muscle hyperplasia.[2]
- Post-exercise muscle repair — Localized MGF injection post-exercise is theorized to amplify the endogenous MGF response and accelerate muscle recovery. The extremely short half-life of native MGF makes the timing of administration critical.[4]
- Sarcopenia research — The observation that MGF expression declines with age has led to interest in MGF as a potential countermeasure for age-related muscle loss. Hameed et al. showed blunted MGF response to exercise in elderly subjects.[5]
- Cardiac repair investigation — MGF is expressed in damaged cardiac tissue following myocardial infarction. Its role in cardiac progenitor cell activation and potential cardiac repair applications are under investigation, though this research is at a very early stage.
- Neuroprotection research — Preliminary studies have suggested MGF expression in neural tissue following injury, with potential neuroprotective effects, though this remains a speculative application.
Contraindications
No established human contraindications exist for MGF, as no human trials have been conducted. The following precautions are based on the pharmacological profile of IGF-1 splice variants and theoretical concerns:
- Active cancer or history of cancer — As an IGF-1 splice variant, MGF is a growth factor that promotes cell proliferation. The IGF-1 signaling axis is implicated in multiple cancers. Use in individuals with active malignancy or a history of cancer is strongly discouraged.
- Pregnancy and lactation — No reproductive safety data exists for synthetic MGF peptide. Growth factor administration during pregnancy poses theoretical risks. Use during pregnancy or breastfeeding is strongly discouraged.
- Cardiac conditions — MGF is expressed in damaged cardiac tissue following myocardial injury. The implications of exogenous MGF administration in individuals with existing cardiac conditions (heart failure, cardiomyopathy, recent MI) are unclear and could be harmful. Exercise caution.
- Known hypersensitivity — Discontinue use if signs of allergic reaction develop.
- Pediatric use — No safety or efficacy data exists for use in children or adolescents.
Standard Protocols
The following protocols are derived entirely from community-reported use and theoretical extrapolation from preclinical studies. No synthetic MGF dosing regimen has been validated in human clinical trials. These should not be interpreted as medical prescriptions.
| Form | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| MGF (non-PEGylated) | IM (local) | 200 – 400 mcg/site | Post-exercise, per target muscle | 4–6 weeks |
| PEG-MGF | SubQ or IM | 200 mcg | 2–3x per week | 4–6 weeks |
Due to the extremely short half-life of non-PEGylated MGF (~5–7 minutes), intramuscular injection directly into the target muscle immediately post-exercise is the standard protocol. The rationale is to deliver the peptide locally before systemic degradation occurs, mimicking the autocrine/paracrine action of endogenous MGF. Bilateral injections (splitting the dose between two sites in the same muscle) are commonly reported.
PEGylated MGF (PEG-MGF) has an extended half-life of several hours, allowing for less frequent dosing and subcutaneous administration. However, PEGylation may alter tissue distribution and biological activity compared to the native peptide fragment.
Common Stacks & Synergies
MGF is frequently combined with other peptides in self-experimentation protocols. The following combinations are commonly reported but lack published clinical evidence:
- MGF + IGF-1 LR3 — The most discussed combination. The proposed rationale is that MGF activates and expands the satellite cell pool (proliferation phase), while IGF-1 LR3 subsequently drives their differentiation and fusion into mature muscle fibers. Some protocols administer MGF immediately post-exercise and IGF-1 LR3 on non-training days or several hours later.
- MGF + GH Secretagogues (CJC-1295/Ipamorelin) — Elevated GH/IGF-1 axis activity is theorized to support the anabolic environment that MGF-activated satellite cells require for proliferation and subsequent differentiation.
- MGF + TB-500 / BPC-157 — Some protocols combine MGF with tissue repair peptides, theorizing that satellite cell activation (MGF) combined with enhanced angiogenesis and tissue repair signaling (TB-500/BPC-157) would accelerate muscle recovery.
Preparation & Administration
MGF is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 2 mg or 5 mg of peptide. It must be reconstituted with bacteriostatic water before injection.
Reconstitution
For a standard 2 mg vial reconstituted with 1 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 200 mcg. For a 400 mcg dose, draw 0.2 mL (20 units). For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.
Injection
Non-PEGylated MGF is typically administered via intramuscular injection directly into the target muscle, immediately after exercise. The injection should be as close to the worked muscle as practical due to the extremely rapid degradation of the peptide. Use a 29–31 gauge insulin syringe. For larger muscles, some protocols split the dose bilaterally (e.g., 200 mcg per side for a bilateral quad injection). For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.
Timing Considerations
Given the ~5–7 minute half-life of non-PEGylated MGF, the window for effective administration is extremely narrow. Reconstituted MGF should be prepared before the training session and injected within minutes of completing the exercise for the target muscle group. Any delay significantly reduces the already-questionable effective exposure time.
Side Effects & Adverse Events
There is virtually no human safety data for synthetic MGF peptide. The adverse event profile below is drawn from theoretical pharmacological considerations and uncontrolled self-reports. The true incidence and severity of side effects in humans is entirely unknown.
Due to the extremely limited data, the known side effect profile of synthetic MGF is sparse. The following are reported or theoretically anticipated:
- Injection site pain and swelling — The most commonly self-reported side effect, consistent with intramuscular injection of any peptide solution into recently exercised (and therefore inflamed) muscle tissue.
- Mild hypoglycemia — As an IGF-1-related peptide, MGF may have minor insulin-like metabolic activity, though this is expected to be significantly less pronounced than with IGF-1 LR3 due to the absence of the mature IGF-1 core sequence in the synthetic 24-AA fragment.
- Localized inflammatory response — Injection into post-exercise muscle may transiently amplify local inflammation.
- Fatigue — Infrequently self-reported, though difficult to distinguish from post-exercise fatigue.
The absence of reported side effects should not be interpreted as evidence of safety. The extremely limited use of synthetic MGF and the absence of any systematic safety monitoring means that rare or delayed adverse effects would be unlikely to be detected or reported.
Drug Interactions
No formal drug interaction studies have been conducted with synthetic MGF peptide. The following theoretical interactions are based on the peptide's relationship to the IGF-1 signaling axis:
- Insulin and insulin secretagogues — Theoretical additive hypoglycemia risk, though likely less significant than with IGF-1 LR3 due to MGF's short half-life and lack of the mature IGF-1 binding domain.
- Anti-cancer therapies — As a growth factor, MGF could theoretically antagonize anti-proliferative cancer therapies. Concurrent use with any cancer therapy should be avoided.
- Immunosuppressants — The effects of exogenous MGF on immune function are unknown. Exercise caution with concurrent immunosuppressive therapy.
- NSAIDs and anti-inflammatory agents — Some protocols specifically avoid NSAIDs around MGF administration, theorizing that the inflammatory response to exercise is part of the signaling cascade that MGF amplifies. The clinical significance of this interaction is unknown.
Storage & Handling
| Form | Condition | Stability |
|---|---|---|
| Lyophilized powder (sealed) | Refrigerated (2–8°C / 36–46°F) | Stable for months |
| Lyophilized powder (sealed) | Frozen (−20°C / −4°F) | Optimal for long-term storage |
| Reconstituted solution | Refrigerated (2–8°C / 36–46°F) | Use within 7–14 days |
| Reconstituted solution | Room temperature | Not recommended; use within hours if unavoidable |
MGF is a small peptide (24 amino acids) and may be more susceptible to degradation in solution than larger proteins. Do not freeze reconstituted solution. Protect from prolonged light exposure and avoid vigorous shaking during reconstitution (swirl gently). If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Use bacteriostatic water for reconstitution to provide antimicrobial preservation for multi-dose use. Given the short recommended stability window, prepare only enough reconstituted solution for near-term use.
Legal & Regulatory Status
- FDA (United States) — MGF is not approved for any indication. It is sold under the research chemical designation "not for human consumption." No investigational new drug (IND) applications for synthetic MGF are publicly known.
- WADA (World Anti-Doping Agency) — MGF and all IGF-1 splice variants are listed on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). They are banned at all times (both in-competition and out-of-competition). Athletes subject to WADA testing must not use MGF.
- European Union — Not approved as a medicinal product. Available as a research chemical with varying regulatory status by member state.
- Australia (TGA) — Not approved. Classified as a prescription-only substance under the Poisons Standard.
Open Questions
The MGF evidence base has fundamental gaps that undermine confident assessment of its utility. Key unresolved questions include:
- Does the 24-AA fragment recapitulate full MGF biology? — This is the central unresolved question. Published research on MGF primarily uses gene expression analysis, gene transfer, or the full-length MGF protein. The commercially available 24-amino-acid C-terminal peptide fragment lacks the mature IGF-1 core sequence. Whether this fragment alone can activate satellite cells and produce the effects attributed to full-length MGF is undemonstrated.[1]
- Practical utility given 5–7 minute half-life — The extremely rapid degradation of non-PEGylated MGF raises serious questions about whether a single bolus injection can deliver sufficient exposure time to produce meaningful biological effects. The endogenous MGF response involves sustained local expression over hours, not a brief spike.
- PEGylated vs. native MGF — PEGylation addresses the half-life problem but may alter tissue distribution, receptor binding, and biological activity. The relative efficacy of PEG-MGF versus native MGF peptide has not been systematically compared.
- Cardiac implications — MGF is expressed in damaged cardiac tissue. Whether exogenous MGF administration is beneficial or harmful in individuals with cardiac disease is unknown and potentially consequential.
- Single research group provenance — The foundational MGF research originates predominantly from a single laboratory (Goldspink et al.). Independent replication by other groups is limited, which is a methodological concern.
- Product quality and consistency — As an unregulated research chemical, the purity, accurate peptide content, sterility, and endotoxin levels of commercially available MGF products cannot be guaranteed.
Bibliography
- Goldspink G. "Mechanical signals, IGF-I gene splicing, and muscle adaptation." Physiology (Bethesda). 2005;20:232-8. doi:10.1152/physiol.00004.2005. PMID:16024511.
- Yang SY, Goldspink G. "Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation." FEBS Lett. 2002;522(1-3):156-60. doi:10.1016/s0014-5793(02)02918-6. PMID:12095637.
- Goldspink G. "Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping." Br J Sports Med. 2005;39(11):787-8. doi:10.1136/bjsm.2004.015826. PMID:16244184.
- Hill M, Goldspink G. "Expression and splicing of the insulin-like growth factor gene in rodent muscle is associated with muscle satellite (stem) cell activation following local tissue damage." J Physiol. 2003;549(Pt 2):409-18. doi:10.1113/jphysiol.2002.035832. PMID:12692175.
- Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD. "Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise." J Physiol. 2003;547(Pt 1):247-54. doi:10.1113/jphysiol.2002.032136. PMID:12562960.